This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Journal and News Scan
Extracorporeal membrane oxygenation (ECMO) can be effective for refractory acute respiratory distress syndrome (ARDS) in patients with influenza, but its utility in patients with coronavirus disease 2019 (COVID-19) is uncertain. We compared outcomes of patients with refractory ARDS from COVID-19 and influenza placed on ECMO.
Repair of complete atrioventricular septal defect (cAVSD) is achieved with low mortality. However, there is a high rate of reoperation on the left atrioventricular valve (LAVV), which is often attributed to nonclosure of the cleft. Although nonclosure of the cleft has been reported to be a risk factor for reoperation, no randomized controlled or propensity-matched trials have ever been performed. We investigated the effect of cleft closure on outcomes after cAVSD repair.
An epidemic in the United States is Heart failure, and transplantation remains the most definitive therapy. We describe multidecade trends in posttransplant graft survival, adjusted for concurrent changes in the population, over the 30 years antecedent to the most recent heart allocation policy change.
On April 20, 2020, Terumo Aortic announced that the US FDA has granted approval for the Thoraflex Hybrid frozen elephant trunk prothesis.
This is the first FET prosthesis commercially available in the US and will bring a new viable treatment option for patients with diseases of the aortic arch and descending aorta.
Interesting manuscript on the immunology of coronary atheroma, with tanslational potential in therapies and prevention of ischaemic heart disease.
This 10-year follow-up of the ROBY study reports on the primary end points of all-cause death and the composite of death or revascularization among 2203 patients randomized to off-pump or on-pump CABG 2002-2007. Death rates at 10 years were 34.2% for off-pump and 31.1% for on-pump. The composite end point was reached at 4.6 years for off-pump and 5.0 years for on-pump. The study identified no advantages for off-pump bypass related to these 10-year outcomes.
Segmentectomy is rising in popularity as a parenchyma-sparing alternative for anatomic lung resection. This study sought to investigate temporal changes in patient selection, case volume, and outcomes for segmentectomy using the Society of Thoracic Surgeons (STS) National Database.
This study both examined the outcomes of children (<18 years) operated on for anomalous left coronary artery from the pulmonary artery (ALCAPA) and linked patients undergoing ALCAPA repair between 1982 and 2003 in the Pediatric Cardiac Care Consortium with the National Death Index and the Organ Procurement and Transplantation Network to examine their outcomes through 2019.
This study from the Canadian Ross Registry evaluated 466 consecutive patients who underwent a Ross procedure using a decellularized cryopreserved pulmonary homograft and evaluated for pulmonary homograft dysfunction. They demonstrate that the cumulative incidence of pulmonary homograft dysfunction was 11% at 6 years with pulmonary homograft stenosis (93%) being the most frequent cause, with an incidence of homograft reintervention of 3% at 6 years.
The Society of Thoracic Surgeons current (STS) guidelines recommend delaying coronary artery bypass graft surgery (CABG) for several days or performing platelet function testing in stable patients who received P2Y12 inhibitors. Their program routinely uses thromboelastography-platelet mapping (TEG-PM) to expedite CABG in P2Y12 nonresponders. They hypothesize that P2Y12 nonresponders had no difference in length of stay to surgery and blood product transfusion compared with patients undergoing urgent inpatient CABG not treated with a P2Y12 inhibitor.